JPRN-jRCT2080220352未知3 期
Phase III clinical study of AFT-801 (confirmatory study) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patients
Mitsubishi Tanabe Pharma Alfresa Pharma Corporation0 个研究点开始时间: 2007年2月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •[Inclusion Criteria]
- •Patients with a confirmed diagnosis of obstructive sleep apnea syndrome, Patients who have used a CPAP machine for at least three months and are able to continue its use during the study period, Patients aged >=20 and =<70 years, etc.
- •[Exclusion Criteria]
- •Patients with existing narcolepsy, periodic limb movement disorder or central sleep apnea syndrome, Patients who work irregular hours or at night, Patients with chronic lack of sleep or irregular bedtime, etc.
排除标准
- 未提供
研究者
相似试验
未知
3 期
Phase 3 clinical study of AFT-801(confirmatory study 0305) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220749Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
未知
3 期
Phase III clinical study of AFT-801 (long-term administration study) Open-label study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220353Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
未知
3 期
AJH801 Phase III Comparative Clinical Study in individuals with essential hypertensioHypertensionJPRN-jRCT2080221447Ajinomoto Pharmaceuticals Co., Ltd.600
已完成
3 期
Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugsAcute ischemic stroke (excluding cardioembolic stroke)JPRN-UMIN000000758Asahi Kasei Pharma Corporation770
未知
2 期
Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensioPulmonary arterial hypertensionJPRN-jRCT2080220801ASAHI KASEI PHARMA CORPORATIO